Type 1 diabetes and type 2 diabetes have high rates of associated exocrine pancreatic insufficiency (EPI). This review evaluated the current evidence on prevalence and treatment of EPI in type 1 and type 2 diabetes and compared general population prevalence rates of EPI and prevalence of other common gastrointestinal conditions such as celiac disease and gastroparesis based on within-diabetes rates of common gastrointestinal (GI) conditions. Prevalence of EPI in type 1 diabetes ranges from 14% to 77.5% (median 33%), while EPI in type 2 diabetes ranges from 16.8% to 49.2% (median 29%), and where type of diabetes is not specified in studies, ranges from 5.4% to 77%. In studies with control groups of the general population, prevalence of EPI overall in those without diabetes ranged from 4.4% to 18%, median 13%, which is comparable with other estimated general population prevalence rates of EPI (10%–20%). Cumulatively, this suggests there may be significant numbers of people with diabetes with EPI who are undiagnosed. People with diabetes (both type 1 and type 2) who present with gastrointestinal symptoms, such as steatorrhea or changes in stool, bloating, and/or abdominal pain, should be screened for EPI. Both diabetes specialists and gastroenterologists and primary care providers should be aware of the high rates of prevalence of diabetes and EPI and recommend fecal elastase-1 screening for people with diabetes and GI symptoms.
Get full access to this article
View all access options for this article.
References
1.
Diéguez-CastilloC, Jiménez-LunaC, PradosJ, et al.State of the art in exocrine pancreatic insufficiency. Medicina (B Aires), 2020; 56(10):523; doi: 10.3390/medicina56100523
CapursoG, TrainiM, PiciucchiM, et al.Exocrine pancreatic insufficiency: prevalence, diagnosis, and management. Clin Exp Gastroenterol, 2019; 12:129–139; doi: 10.2147/CEG.S168266
4.
ForsmarkC. Diagnosis and management of exocrine pancreatic insufficiency. Curr Treat Options Gastro, 2018; 16:306–315.
5.
ForsmarkCE, TangG, XuH, et al.The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. Aliment Pharmacol Ther, 2020; 51(10):958–967; doi: 10.1111/apt.15698
6.
DugganSN, SmythND, MurphyA, et al.High prevalence of osteoporosis in patients with chronic pancreatitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol, 2014; 12(2):219–228; doi: 10.1016/j.cgh.2013.06.016
7.
ScotetV, L'hostisC, FérecC. The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTRGene discovery. Genes (Basel), 2020; 11(6):589; doi: 10.3390/genes11060589
8.
PetrovMS, YadavD. Global epidemiology and holistic prevention of pancreatitis. Nat Rev Gastroenterol Hepatol, 2019; 16(3):175–184; doi: 10.1038/s41575-018-0087-5
9.
LippiG, MattiuzziC. The global burden of pancreatic cancer. Arch Med Sci, 2020; 16(4):94845; doi: 10.5114/aoms.2020.94845
10.
CampbellJ, FrancisK, KurienM, et al.PWE-208 How common is pancreatic exocrine insufficiency in primary care?. Gut, 2015; 64(Suppl 1):655; doi: 10.1136/gutjnl-2015-309861.655
11.
RothenbacherD, LöwM, HardtPD, et al.Prevalence and determinants of exocrine pancreatic insufficiency among older adults: Results of a population-based study. Scand J Gastroenterol, 2005; 40(6):697–704; doi: 10.1080/00365520510023116
12.
RadlingerB, RamoserG, KaserS. Exocrine pancreatic insufficiency in type 1 and type 2 diabetes. Curr Diab Rep, 2020; 20(6):18; doi: 10.1007/s11892-020-01304-0
13.
HartPA, ConwellDL. Challenges and updates in the management of exocrine pancreatic insufficiency. Pancreas, 2016; 45(1):1–4; doi: 10.1097/MPA.0000000000000457
14.
LindkvistB. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol, 2013; 19(42):7258; doi: 10.3748/wjg.v19.i42.7258
15.
PhillipsME, HopperAD, LeedsJS, et al.Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol, 2021; 8(1):e000643; doi: 10.1136/bmjgast-2021-000643
16.
RockwernSS, SnivelyD. Pancreatic lithiasis associated with pancreatic insufficiency and diabetes mellitus: Report of two cases. Arch Intern Med, 1940; 65(5):873; doi: 10.1001/archinte.1940.00190110002001
17.
VaccaJB. The exocrine pancreas in diabetes mellitus. Ann Intern Med, 1964; 61(2):242; doi: 10.7326/0003-4819-61-2-242
18.
CheyWY, ShayH, ShumanCR. External pancreatic secretion in diabetes mellitus. Ann Intern Med, 1963; 59:812–821; doi: 10.7326/0003-4819-59-6-812
19.
CanawayS, PhillipsI, BettsP. Pancreatic exocrine insufficiency and type 1 diabetes mellitus. Br J Nurs, 2000; 9(18):2030–2032; doi: 10.1296/8/bjon.2000.9.18.12461
20.
IcksA, HaastertB, GianiG, et al.Low fecal elastase-1 in type I diabetes mellitus. Z Gastroenterol, 2001; 39(10):823–830; doi: 10.1055/s-2001-17867
21.
NunesACR, PontesJM, RosaA, et al.Screening for pancreatic exocrine insufficiency in patients with diabetes mellitus. Am J Gastroenterol, 2003; 98(12):2672–2675; doi: 10.1111/j.1572-0241.2003.08730.x
22.
HardtPD, KraussA, BretzL, et al.Pancreatic exocrine function in patients with type 1 and type 2 diabetes mellitus. Acta Diabetol, 2000; 37(3):105–110; doi: 10.1007/s005920070011
23.
HardtPD, HauenschildA, NalopJ, et al.High prevalence of exocrine pancreatic insufficiency in diabetes mellitus: A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology, 2003; 3(5):395–402; doi: 10.1159/000073655
24.
RathmannW, HaastertB, IcksA, et al.Low faecal elastase 1 concentrations in type 2 diabetes mellitus. Scand J Gastroenterol, 2001; 36(10):1056–1061; doi: 10.1080/003655201750422657
25.
LaassMW, HenkerJ, ThammK, et al.Exocrine pancreatic insufficiency and its consequences on physical development and metabolism in children and adolescents with type 1 diabetes mellitus. Eur J Pediatr, 2004; 163(11):681–682; doi: 10.1007/s00431-004-1501-2
26.
HahnJU, KernerW, MaisonneuveP, et al.Low fecal elastase 1 levels do not indicate exocrine pancreatic insufficiency in type-1 diabetes mellitus. Pancreas, 2008; 36(3):274–278; doi: 10.1097/MPA.0b013e3181656f8
27.
HardtPD. Comment on “Low Fecal Elastase 1 Levels Do Not Indicate Exocrine Pancreatic Insufficiency in Type-1 Diabetes Mellitus (Pancreas 2008;36:274–278).”. Pancreas, 2009; 38(4):471–472; doi: 10.1097/MPA.0b013e31818b0060
28.
FosterTP, BruggemanB, Campbell-ThompsonM, et al.Exocrine pancreas dysfunction in type 1 diabetes. Endocr Pract, 2020; 26(12):1505–1513; doi: 10.4158/EP-2020-0295
29.
HardtPD, EwaldN. Exocrine pancreatic insufficiency in diabetes mellitus: A complication of diabetic neuropathy or a different type of diabetes?. Exp Diabetes Res, 2011; 2011:761950; doi: 10.1155/2011/761950
30.
VujasinovicM, ZaletelJ, TepesB, et al.Low prevalence of exocrine pancreatic insufficiency in patients with diabetes mellitus. Pancreatology, 2013; 13(4):343–346; doi: 10.1016/j.pan.2013.05.010
31.
CummingsM. Pancreatic exocrine insufficiency in type 1 and type 2 diabetes—More common than you think?. J Diabetes Nurs, 2014; 18(8):320–323.
32.
TerzinV, VárkonyiT, SzabolcsA, et al.Prevalence of exocrine pancreatic insufficiency in type 2 diabetes mellitus with poor glycemic control. Pancreatology, 2014; 14(5):356–360; doi: 10.1016/j.pan.2014.07.004
33.
CummingsMH, ChongL, HunterV, et al.Gastrointestinal symptoms and pancreatic exocrine insufficiency in type 1 and type 2 diabetes. Pract Diabetes, 2015; 32(2):54–58; doi: 10.1002/pdi.1924
34.
ShivaprasadC, PulikkalAA, Prasanna KumarKM. Pancreatic exocrine insufficiency in type 1 and type 2 diabetics of Indian origin. Pancreatology, 2015; 15(6):616–619; doi: 10.1016/j.pan.2015.09.018
35.
DemirK, KaracaC, AhishaliE, et al.A cross-sectional study to assess the prevalence of pancreatic exocrine insufficiency among diabetes mellitus patients in Turkey. Pancreas, 2016; 45(7):e39–e40; doi: 10.1097/MPA.0000000000000626
36.
ZhangJ, HouJ, LiuD, et al.The prevalence and characteristics of exocrine pancreatic insufficiency in patients with type 2 diabetes: A systematic review and meta-analysis. Int J Endocrinol, 2022; 2022:1–9; doi: 10.1155/2022/7764963
37.
MohapatraS, MajumderS, SmyrkTC, et al.Diabetes mellitus is associated with an exocrine pancreatopathy: Conclusions from a review of literature. Pancreas, 2016; 45(8):1104–1110; doi: 10.1097/MPA.0000000000000609
38.
SøftelandE, PoulsenJL, Starup-LindeJ, et al.Pancreatic exocrine insufficiency in diabetes mellitus—Prevalence and characteristics. Eur J Intern Med, 2019; 68:18–22; doi: 10.1016/j.ejim.2019.07.021
39.
AksozZ, AkkanT, BeyanE, et al.The easy way of evaluating exocrine pancreatic insufficiency in type 2 diabetes: Listen to the patients' complaints and look in their eyes!. Acta Gastroenterol Belg, 2020; 83(3):407–412.
40.
SangnesDA, Sandvik BergmannE, MossRM, et al.Pancreatic exocrine insufficiency in diabetes is associated with autonomic dysfunction. Scand J Gastroenterol, 2021; 56(10):1222–1228; doi: 10.1080/00365521.2021.1957496
41.
AnoopS, DasguptaR, JebasinghFK, et al.Exocrine pancreatic insufficiency related fat malabsorption and its association with autonomic neuropathy in Asian Indians with type 2 diabetes mellitus. Diabetes Metab Syndr, 2021; 15(5):102273; doi: 10.1016/j.dsx.2021.102273
42.
JohnstonPC, ThompsonJ, RobertsB, et al.Faecal elastase testing and factors linked with development of pancreatic exocrine insufficiency in diabetes: The Belfast Trust experience. Pract Diabetes, 2022; 39(4):38–41; doi: 10.1002/pdi.2409
43.
SunH, SaeediP, KarurangaS, et al.IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract, 2022; 183:109119; doi: 10.1016/j.diabres.2021.109119
44.
PyensonB, AlstonM, GombergJ, et al.Applying machine learning techniques to identify undiagnosed patients with exocrine pancreatic insufficiency. J Health Econ Outcomes Res, 2019; 6(2):32–46; doi: 10.3646/9/9727
45.
MohanV, PoongothaiS, PitchumoniCS. Oral pancreatic enzyme therapy in the control of diabetes mellitus in tropical calculous pancreatitis. Int J Pancreatol, 1998; 24(1):19–22; doi: 10.1007/BF02787526
46.
WhitcombDC, BodhaniA, BeckmannK, et al.Efficacy and safety of pancrelipase/pancreatin in patients with exocrine pancreatic insufficiency and a medical history of diabetes mellitus. Pancreas, 2016; 45(5):679–686; doi: 10.1097/MPA.0000000000000514
47.
ZsóriG, IllésD, TerzinV, et al.Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: Do we need to treat it? A systematic review. Pancreatology, 2018; 18(5):559–565; doi: 10.1016/j.pan.2018.05.006
48.
Alexandre-HeymannL, MalloneR, BoitardC, et al.Structure and function of the exocrine pancreas in patients with type 1 diabetes. Rev Endocr Metab Disord, 2019; 20(2):129–149; doi: 10.1007/s11154-019-09501-3
49.
BasturkA, CurekY, FelekR, et al.Exocrine pancreas functions in children with type 1 diabetes mellitus. Arab J Gastroenterol, 2021; 22(3):236–239; doi: 10.1016/j.ajg.2021.05.018
50.
EwaldN, BretzelRG, FantusIG, et al.Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a prospective multi-centre trial. Diabetes Metab Res Rev, 2007; 23(5):386–391; doi: 10.1002/dmrr.708
51.
VárkonyiT, SzabolcsA, SzidorV, et al.Assessment of the exocrine pancreatic dysfunction and the effects of enzyme substitution in patients with non-pancreatic diabetes. Z Gastroenterol, 2010; 48(5):1254834; doi: 10.1055/s-0030-1254834
52.
LewisDM, ShahidA. Glycemic variability assessment in newly treated exocrine pancreatic insufficiency with type 1 diabetes. J Diabetes Sci Technol, 2022; 2022:193229682211084; doi: 10.1177/19322968221108414
53.
Domínguez-MuñozJE, Nieto-GarciaL, López-DíazJ, et al.Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: A retrospective analysis. BMC Cancer, 2018; 18(1):534 doi: 10.1186/s12885-018-4439-x
MorawskiJH, PrüfertA, Van EngenA, et al.Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. J Med Econ, 2012; 15(Suppl 1):15–25; doi: 10.3111/13696998.2012.737882
56.
GardnerTB, MunsonJC, MordenNE. The FDA and prescription pancreatic enzyme product cost. Am J Gastroenterol, 2014; 109(5):624–625; doi: 10.1038/ajg.2013.430
57.
TrangT, ChanJ, GrahamDY. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century. World J Gastroenterol, 2014; 20(33):11467–11485; doi: 10.3748/wjg.v20.i33.11467
58.
LewisD. Costs, Price and Calculations for Living With Diabetes and Exocrine Pancreatic Insufficiency and Celiac and Graves; 2022. Available from: https://diyps.org/2022/11/16/costs-price-and-calculations-for-living-with-diabetes-and-exocrine-pancreatic-insufficiency-and-celiac-and-graves/ [Last accessed: January11, 2023]
59.
GardnerT, GordonS. Sacrificing affordability in the name of proving efficacy: The case of pancreatic enzyme replacement therapy. Am J Gastroenterol, 2013; 108:224; doi: 10.1430/9/00000434-201310001-00224
60.
YangW, DallTM, BeronjiaK, et al.Economic costs of diabetes in the U.S. in 2017. Diabetes Care, 2018; 41(5):917–928; doi: 10.2337/dci18-0007
61.
ShandroBM, RitehniaJ, ChenJ, et al.The investigation and management of pancreatic exocrine insufficiency: A retrospective cohort study. Clin Med (Lond), 2020; 20(6):535–540; doi: 10.7861/clinmed.2020-0506
62.
AlbatinehAN, DehvanF, ShariariH, et al.Prevalence of celiac disease in patients with type 1 diabetes: A systematic review and meta-analysis. Clin Diabetol, 2021; 10(6):447–461; doi: 10.5603/DK.2021.0055
63.
BhatiaE. Celiac disease & type 1 diabetes: A double burden. Indian J Med Res, 2019; 149(1):5–7; doi: 10.4103/ijmr.IJMR_1998_18
64.
KylökäsA, KaukinenK, HuhtalaH, et al.Type 1 and type 2 diabetes in celiac disease: Prevalence and effect on clinical and histological presentation. BMC Gastroenterol, 2016; 16(1):76; doi: 10.1186/s12876-016-0488-2
65.
KizilgulM, OzcelikO, BeyselS, et al.Screening for celiac disease in poorly controlled type 2 diabetes mellitus: Worth it or not?. BMC Endocr Disord, 2017; 17(1):62; doi: 10.1186/s12902-017-0212-4
ChoungRS, LockeGR, SchleckCD, et al.Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol, 2012; 107(1):82–88; doi: 10.1038/ajg.2011.310
68.
HuangI, ScholJ, KhatunR, et al.Worldwide prevalence and burden of gastroparesis-like symptoms as defined by the United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United Eur Gastroenterol J, 2022; 10(8):888–897; doi: 10.1002/ueg2.12289
69.
CampbellJ.Is Pancreatic Exocrine Insufficiency an Under-Recognised Diagnosis?. University of Sheffield: Sheffield, United Kingdom; 2017.
70.
CampbellJA, SandersDS, FrancisKA, et al.Should we investigate gastroenterology patients for pancreatic exocrine insufficiency? A dual centre UK study. J Gastrointestin Liver Dis, 2016; 25(3):303–309; doi: 10.1540/3/jgld.2014.1121.253.uks
71.
HerzigKH, PurhonenAK, RäsänenKM, et al.Fecal pancreatic elastase-1 levels in older individuals without known gastrointestinal diseases or diabetes mellitus. BMC Geriatr, 2011; 11:4; doi: 10.1186/1471-2318-11-4
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
